Antigen Binding Proteins that Bind c-Met

Abstract

There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.

1 .- 13 . (canceled) 
     
     
         14 . An anti-c-Met antibody or antigen-binding fragment thereof, comprising all of the complementarity determining regions (CDRs) as set forth in a heavy and light chain variable sequence of SEQ ID NO. 86 and SEQ ID NO. 87, respectively. 
     
     
         15 . The anti-c-Met antibody or antigen-binding fragment thereof of  claim 14 , wherein the antibody has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         16 . The anti-c-Met antibody of  claim 14 , wherein the antibody is a fully human antibody of an IgG class. 
     
     
         17 . The antigen-binding fragment of  claim 14 , wherein the antigen-binding fragment is a fully human anti-c-Met antibody Fab fragment. 
     
     
         18 . The fully human anti-c-Met antibody Fab fragment of  claim 17 , wherein the fragment has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         19 . The antigen-binding fragment of  claim 14 , wherein the antigen-binding fragment is a single chain human anti-c-Met antibody, wherein a peptide linker connects the heavy and light chain variable domain sequences. 
     
     
         20 . The human single chain anti-c-Met antibody of  claim 19 , wherein the single chain human antibody has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         21 . A method for treating cancer, comprising administering to a subject having a cancer expressing c-Met an effective amount of the anti-c-Met antibody of  claim 21 . 
     
     
         22 . The method of  claim 21 , wherein the anti-c-Met antibody has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         23 . The method of  claim 21 , wherein the cancer is a HGF-dependent or HGF-independent c-Met-activation-related cancer. 
     
     
         24 . The method of  claim 21 , wherein the cancer is a prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, glioblastoma, or colon cancer. 
     
     
         25 . A method for treating cancer, comprising administering to a subject having a cancer expressing c-Met an effective amount of the anti-c-Met antibody Fab fragment of  claim 17 . 
     
     
         26 . The method of  claim 25 , wherein the anti-c-Met antibody Fab fragment has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         27 . The method of  claim 25 , wherein the cancer is a HGF-dependent or HGF-independent c-Met-activation-related cancer. 
     
     
         28 . The method of  claim 25 , wherein the cancer is a prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, glioblastoma, or colon cancer. 
     
     
         29 . A method for treating cancer, comprising administering to a subject having a cancer expressing c-Met an effective amount of the single chain anti-c-Met antibody of  claim 19 . 
     
     
         30 . The method of  claim 29 , wherein the single chain anti-c-Met antibody has a heavy chain variable domain sequence of SEQ ID NO. 86 and a light chain variable domain sequence of SEQ ID NO. 87. 
     
     
         31 . The method of  claim 29 , wherein the cancer is a HGF-dependent or HGF-independent c-Met-activation-related cancer. 
     
     
         32 . The method of  claim 29 , wherein the cancer is a prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, glioblastoma, or colon cancer. 
     
     
         33 . An isolated nucleic acid encoding an anti-c-Met antibody, or antigen-binding fragment thereof, comprising all of the complementarity determining regions (CDRs) as set forth in a heavy and light chain variable sequence of SEQ ID NO. 86 and SEQ ID NO. 87, respectively. 
     
     
         34 . The nucleic acid of  claim 33 , wherein the antibody has a heavy chain variable region sequence of SEQ ID NO. 86 and a light chain variable region sequence of SEQ ID NO. 87. 
     
     
         35 . An expression vector comprising the nucleic acid of  claim 34 . 
     
     
         36 . A host cell comprising the nucleic acid of  claim 33 . 
     
     
         37 . A method of making an anti-c-Met antibody, comprising culturing the host cell of  claim 36  under conditions wherein the antibody is expressed.